Status:
COMPLETED
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
Lead Sponsor:
Amgen
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.
Eligibility Criteria
Inclusion
- Man or woman at least 18 years old
- Diagnosis of metastatic colorectal cancer (mCRC)
- One and only one chemotherapy regimen for mCRC consisting of first-line 5-FU -based chemotherapy
- Radiologically documented disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria during treatment or within 6 months of last dose of first-line chemotherapy
- At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST
- Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2
- Paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyses
- Adequate hematologic, renal, and hepatic functions
- Negative pregnancy test within 72 hours of enrollment
- Other protocol-specified criteria may apply
Exclusion
- History of or known presence of central nervous system (CNS) metastases
- History of another primary cancer within 5 years of randomization
- Prior irinotecan therapy
- Prior anti-epidermal growth factor receptor (EGFr) antibody therapy or treatment with small molecule EGFr inhibitors
- Any investigational agent or therapy within 30 days before randomization
- Known allergy or hypersensitivity to irinotecan, 5-FU or leucovorin
- History of interstitial lung disease or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
- Active inflammatory bowel disease or other bowel disease causing chronic diarrhea
- Known positive tests for human immunodefiency virus (HIV), hepatitis C viris (HCV), acute or chronic active hepatitis B virus (HBV)
- Major surgery within 28 days of randomization or minor surgical procedure within 14 days of randomization
- Pregnant or breast-feeding
- Man or woman of child-bearing potential not consenting to use adequate contraceptive methods or abstinence during the course of the study and for 6 months after last study drug administration (women) or 1 month after last study drug administration (men)
- Other protocol-specified criteria may apply
Key Trial Info
Start Date :
June 30 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
1186 Patients enrolled
Trial Details
Trial ID
NCT00339183
Start Date
June 30 2006
End Date
November 1 2010
Last Update
September 23 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.